LifeMD Replaces Citizens Facility with $12.5M Avenue Term Loan and Cuts FY26 Revenue Guidance
LFMD is trading near its 52-week low of $1.6 (6.9% below the low).
Summary
LifeMD closed a $12.5 million secured term loan with Avenue Capital to replace its Citizens facility and cut FY26 revenue guidance to $188-191 million from $205.5-212.5 million, after Q3 revenue fell 7% to $44.6 million.
Key Events · Financing and Capital Events · LFMD
-
New $12.5M Avenue Term Loan
On November 9, 2026, LifeMD and its pharmacy subsidiaries closed a $12.5 million senior secured term loan with Avenue Venture Opportunities Fund II and Avenue Growth Lending Fund III, secured by substantially all borrower assets.
-
Loan Terms and Warrant Coverage
Interest accrues at the greater of Prime plus 4.50% or 11.50%, is interest-only for up to 24 months, and matures May 1, 2030; there is a $125,000 commitment fee and a 3.50% final payment. Lenders also received warrants for $625,000 of stock at the lower of $2.32 or the price of a bona fide equity raise before June 30, 2027 (269,376 shares at $2.32).
-
$150M Revenue Covenant
The loan requires trailing twelve-month net revenue of at least $150 million at each quarter-end starting December 31, 2026, against FY26 guidance of $188-191 million.
-
Guidance Cut After Q3 Miss
Q3 revenue came in at $44.6 million, down 7% year-over-year, and FY26 revenue guidance was cut to $188-191 million from $205.5-212.5 million; adjusted EBITDA guidance fell to negative $12.6 to $10.6 million from negative $6.0 million to breakeven.
Analysis · LFMD · Industrial Applications And Services
The working capital behind LifeMD's new branded GLP-1 fulfillment arrangements now comes with tighter strings. On November 9, the company closed a $12.5 million senior secured term loan with Avenue Capital, replacing its Citizens Bank facility, while cutting full-year 2026 revenue guidance to $188-191 million from $205.5-212.5 million. The loan carries an 11.50% interest floor, a $150 million trailing-twelve-month revenue covenant starting with the December quarter, and warrants for $625,000 of stock. With Q3 revenue down 7% to $44.6 million and adjusted EBITDA guided to a $10.6-12.6 million loss for the year, that covenant leaves little room for another revenue miss.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LFMD was trading at $1.49 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $79.8M. The 52-week trading range was $1.60 to $5.38. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.